RET and non-small cell lung carcinoma: The hard time clinicians are experiencing in treating RET-positive NSCLC was recently confirmed by a retrospective analysis of 53 patients with RET-rearranged NSCLC treated with different RET-inhibitors, with RR up to 37% and median PFS of only 2.3 months [71].